Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Sees Large Drop in Short Interest

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 146,700 shares, a decrease of 14.1% from the February 13th total of 170,700 shares. Based on an average trading volume of 346,000 shares, the short-interest ratio is presently 0.4 days. Approximately 0.9% of the shares of the company are sold short.

Hedge Funds Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. XTX Topco Ltd lifted its holdings in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 351.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 62,903 shares of the company’s stock after buying an additional 48,977 shares during the period. XTX Topco Ltd owned about 0.25% of Sensei Biotherapeutics worth $31,000 at the end of the most recent reporting period. 10.50% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Sensei Biotherapeutics in a research note on Wednesday, January 8th.

Sensei Biotherapeutics Stock Up 0.7 %

SNSE opened at $0.46 on Friday. The business has a 50 day moving average price of $0.47 and a two-hundred day moving average price of $0.50. The company has a market cap of $11.57 million, a PE ratio of -0.39 and a beta of 0.16. Sensei Biotherapeutics has a 52 week low of $0.38 and a 52 week high of $1.94.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.